Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China flag China · Delayed Price · Currency is CNY
49.30
+2.21 (4.69%)
Sep 30, 2026, 4:00 PM EDT

SHE:301096 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
649.58677.49801.151,017607.41374.31
Other Revenue
0.490.490.770.11--
650.08677.99801.921,017607.41374.31
Revenue Growth
6.71%-15.46%-21.18%67.51%62.27%80.61%
Cost of Revenue
413.94416.71389.09352.16198.18122.53
Gross Profit
236.14261.28412.83665.28409.23251.78
Selling, General & Admin
131.58125.4892.69139.65104.4357.41
Research & Development
163.33189.5318.03239.64163.0378.33
Other Operating Expenses
18.294.869.775.4810.370.58
Operating Expenses
340.52343.89458.56404.25286.86140.42
Operating Income
-104.38-82.6-45.73261.04122.37111.36
Interest Expense
-22.6-21.02-16.94-7-1.32-3.67
Interest & Investment Income
5.052.9613.0428.2442.012.27
Currency Exchange Gain (Loss)
-0.03-0.010.01-01.661.37
Other Non Operating Income (Expenses)
-3.2-3.070.78-1.9-1.56-1.36
EBT Excluding Unusual Items
-125.16-103.73-48.84280.37163.16109.98
Gain (Loss) on Sale of Investments
-11.8-11.8-5.59-0.11-3.97-0.65
Gain (Loss) on Sale of Assets
0.440.22-0.780.02-
Asset Writedown
-0-0-0.01-0.03-0.03-0.07
Other Unusual Items
42.2124.1718.3814.6631.749.69
Pretax Income
-94.31-91.14-36.06295.68190.91118.95
Income Tax Expense
-2.41-0.7416.8623.66-3.147.98
Earnings From Continuing Operations
-91.9-90.4-52.92272.01194.04110.97
Minority Interest in Earnings
0-0.18-0.050.120.12
Net Income
-91.9-90.4-52.74271.97194.16111.09
Net Income to Common
-91.9-90.4-52.74271.97194.16111.09
Net Income Growth
---40.07%74.78%93.52%
Shares Outstanding (Basic)
13710910810810881
Shares Outstanding (Diluted)
13710910810810881
Shares Change
30.43%1.18%-0.66%-0.11%33.77%0.29%
EPS (Basic)
-0.67-0.83-0.492.511.801.37
EPS (Diluted)
-0.67-0.83-0.492.511.791.37
EPS Growth
---40.22%30.66%92.96%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
-147.02-252.56-590.96-598.15-332.16-103.02
Free Cash Flow Per Share
-1.07-2.32-5.49-5.52-3.06-1.27
Dividend Per Share
---0.3000.8000.600
Dividend Growth
----62.50%33.33%-
Gross Margin
36.33%38.54%51.48%65.39%67.37%67.27%
Operating Margin
-16.06%-12.18%-5.70%25.66%20.15%29.75%
Profit Margin
-14.14%-13.33%-6.58%26.73%31.97%29.68%
Free Cash Flow Margin
-22.62%-37.25%-73.69%-58.79%-54.68%-27.52%
EBITDA
54.7474.3699.58348.93178.67138.97
EBITDA Margin
8.42%10.97%12.42%34.29%29.42%37.13%
D&A For EBITDA
159.12156.96145.3187.8956.327.61
EBIT
-104.38-82.6-45.73261.04122.37111.36
EBIT Margin
-16.06%-12.18%-5.70%25.66%20.15%29.75%
Effective Tax Rate
---8.00%-6.71%
Revenue as Reported
650.08677.99801.921,017607.41374.31
Advertising Expenses
-2.497.341.721.382.75